LT3484446T - Antikūno kompozicijos - Google Patents

Antikūno kompozicijos

Info

Publication number
LT3484446T
LT3484446T LTEPPCT/EP2017/067870T LTEP2017067870T LT3484446T LT 3484446 T LT3484446 T LT 3484446T LT EP2017067870 T LTEP2017067870 T LT EP2017067870T LT 3484446 T LT3484446 T LT 3484446T
Authority
LT
Lithuania
Prior art keywords
antibody compositions
antibody
compositions
Prior art date
Application number
LTEPPCT/EP2017/067870T
Other languages
English (en)
Inventor
Giovanni Neri
Camilla BACCI
Original Assignee
Philogen S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen S.P.A. filed Critical Philogen S.P.A.
Publication of LT3484446T publication Critical patent/LT3484446T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LTEPPCT/EP2017/067870T 2016-07-15 2017-07-14 Antikūno kompozicijos LT3484446T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1612317.6A GB201612317D0 (en) 2016-07-15 2016-07-15 Antibody compositions
PCT/EP2017/067870 WO2018011404A1 (en) 2016-07-15 2017-07-14 Antibody compositions

Publications (1)

Publication Number Publication Date
LT3484446T true LT3484446T (lt) 2024-11-25

Family

ID=56890667

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2017/067870T LT3484446T (lt) 2016-07-15 2017-07-14 Antikūno kompozicijos

Country Status (15)

Country Link
US (2) US11351257B2 (lt)
EP (2) EP4233843A3 (lt)
DK (1) DK3484446T3 (lt)
ES (1) ES2993464T3 (lt)
FI (1) FI3484446T3 (lt)
GB (1) GB201612317D0 (lt)
HR (1) HRP20241637T1 (lt)
HU (1) HUE069391T2 (lt)
LT (1) LT3484446T (lt)
PL (1) PL3484446T3 (lt)
PT (1) PT3484446T (lt)
RS (1) RS66141B1 (lt)
SI (1) SI3484446T1 (lt)
SM (1) SMT202500088T1 (lt)
WO (1) WO2018011404A1 (lt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206081A (zh) 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
GB201703062D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
US12577297B2 (en) * 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations
US20230312726A1 (en) 2020-04-14 2023-10-05 Philogen S.P.A. Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain b of fibronectin
PT4153232T (pt) * 2020-05-22 2024-10-02 Philogen Spa Terapêutica com imunoconjugado de tnf-a para o tratamento de tumores cerebrais
CN118922207A (zh) 2022-03-21 2024-11-08 菲洛根股份公司 TNFα免疫缀合物制剂
CN119072328A (zh) 2022-03-23 2024-12-03 菲洛根股份公司 Il2免疫缀合物制剂
CN119836298A (zh) * 2022-09-01 2025-04-15 菲洛根股份公司 用于非黑色素瘤皮肤癌的TNFα和白细胞介素-2组合疗法
WO2025172582A1 (en) * 2024-02-15 2025-08-21 Philogen S.P.A Methods for treating melanoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
ATE333900T1 (de) * 2000-02-24 2006-08-15 Philogen Spa Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen
EA200802289A1 (ru) 2006-05-08 2009-04-28 Филоджен Спа Направляемые к мишени антителами цитокины для терапии
US7608261B2 (en) * 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
EP2170390B1 (en) 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations
ES2762179T3 (es) 2011-09-26 2020-05-22 Philogen Spa Terapia de combinación de inmunocitocinas
BR112015027764A2 (pt) * 2013-05-02 2017-08-29 Mabxience S A Formulações alternativas para os polipeptídeos de fusão de tnfr: fc
CN106132434A (zh) 2014-04-07 2016-11-16 西雅图基因公司 抗‑cd19抗体和抗体‑药物偶联物的稳定制剂
CA2941029C (en) * 2014-04-10 2021-02-16 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions

Also Published As

Publication number Publication date
PT3484446T (pt) 2024-11-21
HRP20241637T1 (hr) 2025-02-14
RS66141B1 (sr) 2024-12-31
FI3484446T3 (fi) 2024-11-21
PL3484446T3 (pl) 2025-02-24
SMT202500088T1 (it) 2025-03-12
SI3484446T1 (sl) 2025-01-31
US12023381B2 (en) 2024-07-02
DK3484446T3 (da) 2024-11-04
ES2993464T3 (en) 2024-12-30
EP4233843A2 (en) 2023-08-30
EP3484446B1 (en) 2024-09-25
US20210093720A1 (en) 2021-04-01
GB201612317D0 (en) 2016-08-31
EP4233843A3 (en) 2023-09-27
EP3484446A1 (en) 2019-05-22
US20230165960A1 (en) 2023-06-01
US11351257B2 (en) 2022-06-07
HUE069391T2 (hu) 2025-03-28
WO2018011404A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
IL265844A (en) Anti-lag-3 antibodies and preparations
IL262176A (en) Anti-tim-3 antibodies and preparations
IL261792B (en) Preparations
IL251282A0 (en) Preparations containing anti-il-7r antibody
IL260933A (en) Preparations containing tocorsol or its analogues
PT3484446T (pt) Composições de anticorpos
GB201610156D0 (en) Cliptac compositions
IL260083A (en) Antibody against myl9
GB201600075D0 (en) Immunogenci composition
GB201622161D0 (en) Compositions
GB201614799D0 (en) Compositions
GB201612658D0 (en) Composition
GB201611782D0 (en) Composition
GB201902573D0 (en) Composition
GB201612359D0 (en) Composition
GB201602658D0 (en) Compositions
GB201607924D0 (en) Composition
GB201620914D0 (en) Composition
GB201614230D0 (en) Compositions
GB201611960D0 (en) Compositions
GB201611851D0 (en) Compositions
GB201618062D0 (en) Composition
GB201602656D0 (en) Compositions
GB201610688D0 (en) Composition
GB201610707D0 (en) Composition